HIV PrEP Options — Medical Practice MCQ

Instant feedback + full explanation. One question, done properly.

ModerateInfectious DiseasesHIV PrEP Options

A 59-year-old on cabotegravir long-acting injections for HIV PrEP asks about alternatives due to injection fatigue. According to CDC, which PrEP options are approved in the U.S. (patient >=35 kg, not pregnant)?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — TDF/FTC daily oral, TAF/FTC daily oral (not for receptive vaginal sex), and long-acting injectable agents (e.g., cabotegravir; newer options per CDC updates)

Correct answer: C. For this CDC/U.S.-licensing question, approved PrEP options for an adult or adolescent weighing at least 35 kg include daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), daily oral emtricitabine/tenofovir alafenamide (FTC/TAF) for sexual transmission except where risk is through receptive vaginal sex, and long-acting injectable PrEP. Cabotegravir is given every 2 months; CDC has also added 6-monthly injectable lenacapavir as a PrEP option after FDA approval in 2025. Therefore, oral FTC/TDF is not the only option, FTC/TAF is not approved for all exposure types, and event-driven 2-1-1 FTC/TDF is off-label rather than FDA-approved and is not recommended by CDC. Lenacapavir is not contraindicated for all PrEP patients; it is now a long-acting injectable PrEP option for eligible people.

Reference: CDC HIV Nexus. Clinical Guidance for PrEP, updated 30 April 2026; and Patel RR et al. CDC MMWR: Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025. https://www.cdc.gov/hivnexus/hcp/prep/index.html; https://www.cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm